PLSE

Pulse Biosciences' stock experienced several notable events over the past six months. The company reported Q4 2025 financial results with increased revenue but a GAAP net loss. Positive clinical data for the nPulse Cardiac Catheter System was presented at the AF Symposium in January 2026 and Heart Rhythm 2026 in April 2026. The company commenced enrollment in the NANOPULSE-AF U.S. IDE pivotal clinical trial in early April 2026. Q1 2026 revenue was reported at $0.4 million, missing consensus expectations, with a wider GAAP net loss. Insider purchases were authorized under an equity program, and the stock was upgraded to a Zacks Rank #2 (Buy). The stock price increased by 24.12% over the past six months but experienced recent volatility.